MARKET

CLRB

CLRB

Cellectar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9770
-0.0030
-0.31%
Opening 14:49 09/24 EDT
OPEN
0.9701
PREV CLOSE
0.9800
HIGH
1.000
LOW
0.9700
VOLUME
278.43K
TURNOVER
--
52 WEEK HIGH
2.980
52 WEEK LOW
0.8100
MARKET CAP
59.70M
P/E (TTM)
-1.8905
1D
5D
1M
3M
1Y
5Y
Cellectar Biosciences (NASDAQ:CLRB) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 7h ago
Cellectar Bio's Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer
Benzinga · 2d ago
BRIEF-Cellectar Says Early Data Of Head And Neck Cancer Treatment Suggests Safety And Tolerability
reuters.com · 2d ago
Cellectar Biosciences Announces Completion Of Part A Portion Of Safety And Tolerability Study Of Iopofosine I-131 In Combination With External Beam Radiation
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the completion of the part A
Benzinga · 2d ago
Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer
Initiation of Expansion Cohort of Up to 24 PatientsFLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the ...
GlobeNewswire · 2d ago
Neuroblastoma Drugs Market By Delivery, Type, Systems, End-User 2028
Research Nester published a report titled "- Global Demand Analysis and Opportunity Outlook 2020-2028" which delivers detailed overview of the neuroblastoma drugs market in terms of market segmentation by drug type, by mechanism type, by treatment type, by...
AmericaNewsHour · 09/16 13:33
Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Car...
GlobeNewswire · 09/15 20:01
Penny Stocks to Buy Using Technical Analysis for September 2021
If you've been meaning to invest in penny stocks and learn more about technical analysis, there's no better time than now.
Investopedia · 09/02 19:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLRB. Analyze the recent business situations of Cellectar through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLRB stock price target is 5.58 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 56
Institutional Holdings: 13.29M
% Owned: 21.75%
Shares Outstanding: 61.10M
TypeInstitutionsShares
Increased
18
1.14M
New
11
684.17K
Decreased
5
1.12M
Sold Out
10
3.27M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.34%
Pharmaceuticals & Medical Research
-0.84%
Key Executives
Non-Executive Chairman/Independent Director
Douglas Swirsky
President/Chief Executive Officer/Director
James Caruso
Chief Financial Officer/Vice President
Dov Elefant
Vice President
John Friend
Other
Jarrod Longcor
Director
Asher Alban Chanan-Khan
Independent Director
Frederick Driscoll
Independent Director
Stefan Loren
Independent Director
John Neis
No Data
About CLRB
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer-targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. Its PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The Company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900). The CLR 1900 Series is targeted for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers.

Webull offers kinds of Cellectar Biosciences Inc stock information, including NASDAQ:CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.